Convalescent Plasma to Limit Coronavirus Associated Complications
Convalescent Plasma to Limit Coronavirus Associated Complications
批准号:
10224557
负责人:
DANIEL D KARP
金额:
$984.32万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-24 至 2023-06-30
关键词:
2019-nCoVAdministrative SupplementAdult Respiratory Distress SyndromeAntibodiesApplications GrantsAreaBasic ScienceBiologicalBlindedBloodCOVID-19COVID-19 pandemicCOVID-19 patientCOVID-19 treatmentCancer CenterCase SeriesCause of DeathChildhoodClinicalClinical ResearchClinical SciencesClinical TrialsClinical and Translational Science AwardsCollaborationsCommunitiesCoronavirusDataDeteriorationDevelopmentDiseaseDoctor of MedicineEbolaEconomically Deprived PopulationEducationElderlyEmergency SituationEnrollmentEnvironmentEpidemicFirst Independent Research Support and Transition AwardsGoalsHealth SciencesHealthcareHispanicsHospitalsHumanImmunoglobulin AImmunoglobulin GImmunoglobulin MIncidenceIndividualInfluenzaInfluenza A Virus, H1N1 SubtypeInformaticsInstitutionInstitutional Review BoardsIntubationKnowledgeLesbian Gay Bisexual Transgender QueerLong IslandLung diseasesMalignant NeoplasmsMeaslesMeta-AnalysisMiddle East Respiratory SyndromeNew YorkNew York CityOutcomePatientsPhasePhysiciansPlacebosPlasmaPneumococcal PneumoniaProcessRandomizedReportingResearchResearch ContractsResearch MethodologyResearch PersonnelResearch TrainingResourcesRespiratory FailureRiceRuralSARS-CoV-2 antibodySafetySalineScienceSerumSevere Acute Respiratory SyndromeSouth TexasSpanish fluTexasTherapeuticTimeTrainingTranslational ResearchTranslationsTreatment EfficacyUniversitiesWorkforce Developmentbasebiobankblood productclinical centerclinical data warehousecomputer scienceconvalescent plasmadesigneffective therapyefficacy evaluationexperiencefallsimprovedinfluenza pneumoniainnovationmortality risknext generationnovelpandemic diseasepandemic influenzapatient populationpatient registryphase II trialplacebo controlled trialprogramsrespiratoryscience educationskillstranslational scientisttrial comparingtrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In the first awarded CTSA class, the Center for Clinical and Translational Sciences (CCTS) formed the first
multiple-institution CTSA, with The University of Texas Health Science Center at Houston (UTHSC-H) and The
University of Texas M. D. Anderson Cancer Center (UT MDACC). Since its inception the CCTS has been
achieving the primary goal of the Clinical and Translational Sciences Award (CTSA) program: to accelerate
research to transform healthcare and train the next generation of translational scientists. Our initial proposal
was about bringing individuals and resources together, educating investigators, and building teams. In our
2011 renewal we described our Lowering-The-Barriers program, which focused on removing a large number of
impediments through initiatives such as IRB reciprocity, standard research contracts and subcontracts, clinical
data warehouses, patient registries, and biobanks. Our efforts have been successful and aligned with the
national CTSA program. In this cycle, we bring in 3 new partner institutions to broaden and diversify our
CTSA: The University of Texas Health Science Center at Tyler (northeast Texas, rural, economically
disadvantaged), Rice University (with strengths in computer science, education, and team science),
and The University of Texas Rio Grande Valley (south Texas, education and physician resources to
help our nearby Brownsville Clinical Research Unit perform clinical trials). Together we will effect 5
strategic goals: Strategic Goal 1: To provide our investigators, staff, trainees, and scholars with the
skills and knowledge necessary to advance discoveries and their translation in the new environment of
clinical and translational research (Workforce Development). Strategic Goal 2: To collaborate with all
of our stakeholders in a mutually beneficial way to advance translation by furthering engagement and
team science (Collaboration/Engagement). Strategic Goal 3: To integrate pediatric and geriatric
patients, Hispanic patients with cancer, and the LGBTQ+ community into the full spectrum of clinical
and translational research (Integration). Strategic Goal 4: To advance translational science by
providing novel processes, increasing efficiency, and streamlining research (Methods/Processes).
Strategic Goal 5. To create and apply innovative informatics solutions to advance translational
research, train the CTSA workforce, disseminate best practices, engage communities and integrate
clinical and basic research data (Informatics).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10316843
-
项目类别:
-
资助金额:$185.96万
-
财政年份:2021
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10295669
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2021
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10217650
-
项目类别:
-
资助金额:$40.62万
-
财政年份:2020
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10655023
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10654064
-
项目类别:
-
资助金额:$290.31万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:9983233
-
项目类别:
-
资助金额:$562.2万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10707570
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10215640
-
项目类别:
-
资助金额:$575.06万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Center for Clinical and Translational Sciences (CCTS)
-
批准号:10441621
-
项目类别:
-
资助金额:$562.56万
-
财政年份:2019
-
负责人:DANIEL D KARP
-
依托单位:
Clinical and Translational
-
批准号:7695952
-
项目类别:
-
资助金额:$21.42万
-
财政年份:2008
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:2821778
-
项目类别:
-
资助金额:$14.65万
-
财政年份:1999
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:6173835
-
项目类别:
-
资助金额:$14.98万
-
财政年份:1999
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:6377050
-
项目类别:
-
资助金额:$13.84万
-
财政年份:1999
-
负责人:DANIEL D KARP
-
依托单位:
PRIMARY BREAST CANCER THERAPY GROUP-NSABP
-
批准号:3558508
-
项目类别:
-
资助金额:$6.24万
-
财政年份:1987
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:2084567
-
项目类别:
-
资助金额:$33.44万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:3555878
-
项目类别:
-
资助金额:$29.27万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:2084568
-
项目类别:
-
资助金额:$35.81万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:3555876
-
项目类别:
-
资助金额:$25.25万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
ONCOLOGY
-
批准号:3555871
-
项目类别:
-
资助金额:$4.53万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
EASTERN COOPERATIVE ONCOLOGY GROUP
-
批准号:2084566
-
项目类别:
-
资助金额:$29.32万
-
财政年份:1982
-
负责人:DANIEL D KARP
-
依托单位:
海外基金